Biotech
BioLineRx Class Action Alert: Submit Your Losses to Johnson Fistel
The Class Action Seeks to Recover Damages on Shareholders’ Behalf SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf more...
Biotech
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting more...
Biotech
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event PR Newswire Live video webcast on Wednesday, January 18 th at 10:00 AM ET HOUSTON , January 5, 2023 /PRNewswire/ — CNS more...
Biotech
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan more...
Biotech
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. more...
Biotech
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California–(Newsfile Corp. – January 5, 2023) – The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharmaceuticals, Inc. (“Eiger” or “the Company”) more...
Biotech
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, more...
Biotech
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in more...
Biotech
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, more...
Biotech
EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines
– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 more...